

Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older

*This measure is to be reported for all female patients aged 65 years and older — a minimum of **once** per reporting period.*

Measure description

Percentage of female patients aged 65 years and older who have a central dual-energy X-ray absorptiometry (DXA) measurement ordered or performed at least once since age 60 or pharmacologic therapy¹ prescribed within 12 months

What will you need to report for each female patient for this measure?

If you select this measure for reporting, you will report:

- Whether or not you ordered or performed a central dual-energy X-ray absorptiometry (DXA) measurement at least once since age 60

OR

- Whether or not you prescribed pharmacologic therapy (other than minerals/vitamins) for osteoporosis

What if this process or outcome of care is not appropriate for your patient?

There may be times when it is not appropriate to order or perform a central DXA measurement at least once since age 60 OR prescribe pharmacologic therapy for osteoporosis, due to:

- Medical reasons (eg, not indicated, contraindicated, other medical reason) OR
- Patient reasons (eg, patient declined, economic, social, religious, other patient reason) OR
- System reasons (eg, resources to perform the services not available, insurance coverage/payer-related limitations, other reason attributable to health care delivery system)

In these cases, you will need to indicate which reason applies, specify the reason on the worksheet and in the medical chart. The office/billing staff will then report a code with a modifier that represents these valid reasons (also called exclusions).

¹Pharmacologic therapy: U.S. Food and Drug Administration approved pharmacologic options for osteoporosis prevention and/or treatment of postmenopausal osteoporosis include, in alphabetical order: bisphosphonates (alendronate, ibandronate, and risedronate), calcitonin, estrogens (estrogens and/or hormone therapy), parathyroid hormone [PTH (1-34), teriparatide], and selective estrogen receptor modulators or SERMs (raloxifene).

Osteoporosis

Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older

PQRI Data Collection Sheet

Patient's Name	Practice Medical Record Number (MRN)	Birth Date (mm/dd/yyyy) / /	Gender <input type="checkbox"/> Male <input type="checkbox"/> Female
National Provider Identifier (NPI)		Date of Service	

Clinical Information

Billing Information

Step 1 Is patient eligible for this measure?

	Yes	No	
Patient is aged 65 years and older.	<input type="checkbox"/>	<input type="checkbox"/>	Verify date of birth on claim form.
Patient is female.	<input type="checkbox"/>	<input type="checkbox"/>	Refer to gender on claim form.
There is a CPT E/M Service Code for this visit.	<input type="checkbox"/>	<input type="checkbox"/>	Refer to coding specifications document for list of applicable codes.
If No is checked for any of the above, STOP. Do not report a CPT category II code.			

Step 2 Does patient meet or have an acceptable reason for not meeting the measure?

	Yes	No	
Central Dual-energy X-ray Absorptiometry (DXA) Measurement OR Pharmacologic Therapy¹			Code to be Reported on Line 24D of Paper Claim Form, if Yes (or Service Line 24 of Electronic Claim Form)
DXA ordered	<input type="checkbox"/>	<input type="checkbox"/>	3096F
DXA performed	<input type="checkbox"/>	<input type="checkbox"/>	3095F
Pharmacologic therapy prescribed	<input type="checkbox"/>	<input type="checkbox"/>	4005F
Not prescribed for one of the following reasons:			
• Medical (eg, not indicated, contraindicated, other medical reason)	<input type="checkbox"/>	<input type="checkbox"/>	3096F-1P OR 3095F-1P OR 4005-1P
• Patient (eg, patient declined, economic, social, religious, other patient reason)	<input type="checkbox"/>	<input type="checkbox"/>	3096F-2P OR 3095F-2P OR 4005F-2P
• System (eg, resources to perform the services not available, other reason attributable to health care delivery system)	<input type="checkbox"/>	<input type="checkbox"/>	3096F-3P OR 3095F-3P OR 4005F-3P
Document reason here and in medical chart. _____ _____			If No is checked for all of the above, report 3096F-8P OR 3095F-8P OR 4005F-8P (Central dual energy X-ray absorptiometry [DXA] measurement was not ordered or performed and a pharmacologic therapy for osteoporosis was not prescribed, reason not otherwise specified.)

¹Pharmacologic therapy: U.S. Food and Drug Administration approved pharmacologic options for osteoporosis prevention and/or treatment of postmenopausal osteoporosis include, in alphabetical order: bisphosphonates (alendronate, ibandronate, and risedronate), calcitonin, estrogens (estrogens and/or hormone therapy), parathyroid hormone [PTH (1-34), teriparatide], and selective estrogen receptor modulators or SERMs (raloxifene).

Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older

Coding Specifications

Codes required to document a visit occurred:

A CPT E/M service code is required to identify patients to be included in this measure.

CPT E/M service codes

- 99201, 99202, 99203, 99204, 99205 (office-new patient),
- 99212, 99213, 99214, 99215 (office-established patient),
- 99387 (preventive medicine services — new patient),
- 99397 (preventive medicine services — established patient),
- 99401, 99402, 99403, 99404 (preventive medicine services — individual counseling)

Quality codes for this measure (one of the following for every eligible patient):

CPT II Code descriptors

(Data collection sheet should be used to determine appropriate combination of codes.)

- **CPT II 3096F:** Central Dual-energy X-Ray Absorptiometry (DXA) ordered
- **CPT II 3095F:** Central Dual-energy X-Ray Absorptiometry (DXA) results documented
- **CPT II 4005F:** Pharmacologic therapy (other than minerals/vitamins) for osteoporosis prescribed
- **CPT II 3096F-1P OR 3095F-1P OR 4005F-1P:** Documentation of medical reason(s) for not ordering or performing a central dual energy X-ray absorptiometry (DXA) measurement or not prescribing pharmacologic therapy for osteoporosis
- **CPT II 3096F-2P OR 3095F-2P OR 4005F-2P:** Documentation of patient reason(s) for not ordering or performing central dual energy X-ray absorptiometry (DXA) measurement or not prescribing pharmacologic therapy for osteoporosis
- **CPT II 3096F-3P OR 3095F-3P OR 4005F-3P:** Documentation of system reason(s) for not ordering or performing central dual energy X-ray absorptiometry (DXA) measurement or not prescribing pharmacologic therapy for osteoporosis
- **CPT II 3096F-8P OR 3095F-8P OR 4005F-8P:** Central dual energy X-ray absorptiometry (DXA) measurement was not ordered or performed and a pharmacologic therapy for osteoporosis was not prescribed, reason not otherwise specified

Physician Performance Measures (Measures) and related data specifications, developed by the American Medical Association (AMA) in collaboration with the Physician Consortium for Performance Improvement (the Consortium) and the National Committee for Quality Assurance (NCQA) pursuant to government sponsorship under subcontract 6205-05-054 with Mathematica Policy Research, Inc. under contract 500-00-0033 with Centers for Medicare & Medicaid Services.

These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.

The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and the AMA, (on behalf of the Consortium) or NCQA. Neither the AMA, NCQA, Consortium nor its members shall be responsible for any use of the Measures.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

© 2004-6 American Medical Association and National Committee for Quality Assurance. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, NCQA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the Measures specifications is copyright 2006 American Medical Association

G codes and associated descriptions included in these Measure specifications are in the public domain.

PQRI 2007 Measure 39, Effective Date 07/01/2007
 © 2004-6 American Medical Association and National Committee for Quality Assurance. All rights reserved.
 CPT® copyright 2006 American Medical Association